Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial

Published:2022-12 Issue:12 Volume:21 Page:1099-1109
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Soileau Michael J,Aldred Jason,Budur Kumar,Fisseha Nahome,Fung Victor SC,Jeong Anna,Kimber Thomas E,Klos Kevin,Litvan Irene,O'Neill Daniel,Robieson Weining Z,Spindler Meredith A,Standaert David G,Talapala Saritha,Vaou Eleni Okeanis,Zheng Hui,Facheris Maurizio F,Hauser Robert A

Funder

AbbVie

Publisher

Elsevier BV

Subject

Neurology (clinical)

Reference28 articles.

1. Are dopaminergic neurons selectively vulnerable to Parkinson's disease?;Agid;Adv Neurol,1993

2. Diagnostic criteria for Parkinson disease;Gelb;Arch Neurol,1999

3. Motor and nonmotor complications of levodopa: phenomenology, risk factors, and imaging features;Ray Chaudhuri;Mov Disord,2018

4. Late-stage Parkinson disease;Coelho;Nat Rev Neurol,2012

5. The scientific and clinical basis for the treatment of Parkinson disease (2009);Olanow;Neurology,2009

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Foslevodopa/foscarbidopa (LDp/CDp) in advanced Parkinson’s Disease (aPD): demonstration of savings from a societal perspective in the UK;Journal of Medical Economics;2024-09-10

2. Levodopa-induced dyskinesia: brain iron deposition as a new hypothesis;BioMetals;2024-08-30

3. Subcutaneous foslevodopa in akinetic crisis. A case report from the neurological intensive care unit;Frontiers in Medicine;2024-08-26

4. The PM20D1-NADA pathway protects against Parkinson’s disease;Cell Death & Differentiation;2024-08-22

5. Advances in Brain Stimulation, Nanomedicine and the Use of Magnetoelectric Nanoparticles: Dopaminergic Alterations and Their Role in Neurodegeneration and Drug Addiction;Molecules;2024-07-29